This article addresses the issues of pharmacogenetics and medical-clinical-pharmaceutical ethics. Its scientific relevance lies in the fact that it discusses, at a broad and in-depth level, a topic that permeates the technical training of students in the areas of health sciences, pharmaceutical sciences and medical sciences, revealing its interdisciplinary nature. Its social relevance lies in the fact that it informs the general public about the possibilities of treatments that may be available in a relatively short time, if the government is interested in investing in such ventures. This is an integrative bibliographical research , of an intervening nature, based on authors who are researching the subject and its ethical and bioethical dimensions. If these studies were undertaken, they would improve the living conditions and health of the population, through the increase in the clinical knowledge of doctors and in the performance of pharmacists in their practice. The conclusions reached are that pharmacogenetics, empirically, is already present in the daily lives of clinical pharmacists, who, upon detecting the resistance of a certain pathogen to a pharmacological compound, immediately associate, by deduction and technical knowledge, that all medications belonging to that pharmacological class may have no effect. In the same way, if a patient complains that the drug has had no effect on his or her organism, he or she already deduces that there is a genetic incompatibility between the two, making it necessary to seek a different chemical formula, which may even be just the vehicle used in the composition and not necessarily the active ingredient of the pharmacochemical compound.
Teixeira et al. (Fri,) studied this question.